Lutetium-177 Market Opportunities Fueled by Cyclotron and Reactor-Based Production Technologies

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Lutetium-177 Market Size, Share & Trends Analysis Report By Application (Oncology, Non-Oncology), Type (No-Carrier-Added (NCA) Lu-177, Carrier-Added (CA) Lu-177), Product Type (Approved Drugs, Pipeline Drugs, Investigational Drugs), Scale of Operation (Preclinical, Clinical, Commercial), End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Research Institutions/CROs), Production(Reactor-Based, Cyclotron-Based), Technology (Targeting Ligands, Production Innovations, Combination Therapies)- Market Outlook And Industry Analysis 2034″

According to the latest research by InsightAce Analytic, the Lutetium-177 Market is valued at USD 2.11 Bn in 2024, and it is expected to reach USD 7.41 Bn by the year 2034, with a CAGR of 11.6 during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3024

Lutetium-177 (Lu-177) is a beta-emitting radioisotope employed in targeted radionuclide therapies for the treatment of various cancers. Production of Lu-177 occurs via two principal methods: the direct approach, which involves the irradiation of Lu-176 to produce carrier-added (c.a.) Lu-177 containing isotopic impurities, and the indirect approach, where Yb-176 irradiation yields non-carrier-added (n.c.a.) Lu-177, resulting in a higher-purity product with improved therapeutic efficacy.

As a theranostic agent, Lu-177 combines diagnostic and therapeutic functionalities. It is particularly effective in treating malignancies such as neuroendocrine tumors and prostate cancer, enabling precise tumor imaging followed by targeted radiation delivery to destroy cancer cells while minimizing damage to surrounding healthy tissues. This dual capability enhances treatment precision and contributes to improved clinical outcomes.

The global Lu-177 market is experiencing robust growth, driven by the increasing prevalence of cancer and the expanding adoption of targeted radiopharmaceutical therapies. Market expansion is further supported by advancements in radiolabeling technologies and enhanced accessibility to nuclear medicine infrastructure.

Strategic partnerships among pharmaceutical firms, research institutions, and healthcare providers are playing a pivotal role in market development. For instance, in June 2024, Curium established a long-term collaboration with the Institut Laue-Langevin (ILL) to scale up the production of non-carrier-added Lu-177.

This initiative is aimed at ensuring a reliable supply of the isotope for clinical use, facilitating treatment for a significant number of cancer patients worldwide over the next five years. Such collaborations highlight the growing significance of Lu-177 in advancing personalized oncology therapies.

List of Prominent Players in the Lutetium-177 Market:

• Novartis AG
• Curium
• Telix Pharmaceuticals
• ITM Isotope Technologies
• Eli Lilly (via POINT Biopharma)
• Radiopharm Theranostics
• Advanced Accelerator Applications (AAA)
• Evergreen Theragnostics
• Nusano Inc.
• Nordic Nanovector

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics: Lutetium-177 (Lu-177)

Drivers:

The Lutetium-177 (Lu-177) market is experiencing strong growth, primarily driven by increasing demand for targeted radiotherapy, particularly for the management of neuroendocrine tumors and prostate cancer. Lu-177’s high therapeutic specificity and minimal systemic side effects make it a preferred option in oncology.

Market expansion is further supported by the growing adoption of targeted radionuclide therapies, alongside advancements in radiopharmaceutical technologies that improve production efficiency, delivery systems, and imaging capabilities. Additionally, favorable regulatory frameworks and government support for cancer research and nuclear medicine have streamlined approval processes and facilitated wider clinical adoption.

Challenges:

Despite its growth potential, the Lu-177 market faces several constraints. The production process is complex and resource-intensive, relying on enriched ytterbium, which limits manufacturing capacity and elevates costs. Supply chain challenges and stringent regulatory compliance requirements further restrict scalability and create operational inefficiencies for market participants.

Regional Trends:

North America currently leads the global Lu-177 market, underpinned by a well-developed healthcare infrastructure, strong research and development capabilities, and a supportive regulatory environment. The presence of advanced oncology treatment centers and leading pharmaceutical companies fosters innovation and accelerates the adoption of Lu-177-based therapies.

Substantial government investment in cancer research and domestic production facilities—such as SHINE Technologies’ plant in Wisconsin—enhances supply chain stability and reduces reliance on international imports. Additionally, the region’s significant cancer burden, with an estimated 2,001,140 new cases and 611,720 deaths projected in the U.S. for 2024, further drives demand for advanced targeted treatment options like Lu-177.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3024

Recent Developments:

• In April 2024, The FDA approved Lutetium Lu 177 dotatate (Lutathera) for pediatric patients (12+) with SSTR-positive GEP-NETs, including foregut, midgut, and hindgut tumors. It had previously received approval for adults in 2018.
• In March 2022, The FDA approved Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had previously received androgen receptor pathway inhibition and taxane-based chemotherapy.

Segmentation of Trusted Platform Module Market-

By Application:

• Oncology
• mCRPC
• NETs
• RCC
• Other Cancers
• Non-Oncology
• Arthritis
• Other

By Type:

• Carrier-Added Lutetium-177
• No-Carrier-Added Lutetium-177

By Product Type:

• Approved Drugs
• Pluvicto (Pro)
• Lutathera (Pro)
• Pipeline Drugs
• Investigational Drugs

By Scale of Operation:

• Preclinical
• Clinical
• Commercial

By End-user:

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Research Institutions/CROs

By Production:

• Reactor-Based
• Cyclotron-Based

By Technology:

• Targeting Ligands
• Production Innovations
• Combination Therapies

By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Tags: Lutetium-177 Market